Eli Lilly and Company (LLY) : Analyst Rating Update

Eli Lilly and Company (LLY) : 13 analysts are covering Eli Lilly and Company (LLY) and their average rating on the stock is 1.92, which is read as a Buy. 8 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. However, 1 analysts consider that the stock has more downward risks ahead, hence, they suggest a Strong Sell on the stock. A total of 4 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.

Eli Lilly and Company (LLY) stock is expected to deviate a maximum of $15.96 from the average target price of $94.58 for the short term period. 12 Street Experts have initiated coverage on the stock with the most promising target being $116 and the most muted being $55.

Eli Lilly and Company (NYSE:LLY): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $79.32 and $79.10 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $80.40. The buying momentum continued till the end and the stock did not give up its gains. It closed at $80.02, notching a gain of 0.48% for the day. The total traded volume was 4,669,765 . The stock had closed at $79.64 on the previous day.

Also, Equity analysts at the Brokerage firm Leerink Swann maintains its rating on Eli Lilly and Company (NYSE:LLY). The rating major has initiated the coverage with outperform rating on the shares. The Analysts at Leerink Swann raises the price target from $96 per share to $101 per share. The rating by the firm was issued on May 2, 2016. The company shares have dropped -8.72% from its 1 Year high price. On Sep 17, 2015, the shares registered one year high at $92.85 and the one year low was seen on Mar 17, 2016. The 50-Day Moving Average price is $75.06 and the 200 Day Moving Average price is recorded at $76.14.

Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers, develops, manufactures and market products in two segments: human pharmaceutical products and animal health products. The Companys products are sold in approximately 120 countries. The Companys human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment operates through the Companys Elanco division, which develops, manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States, Puerto Rico and 11 other countries. Its products include endocrinology products, neuroscience products, oncology products, cardiovascular products, products for food animals, products for companion animals and Novartis AH products.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.